南财智讯1月8日电，爱朋医疗公告，北京章泓私募基金管理有限公司-章泓精选1号私募证券投资基金因 自身资金需求，于2025年12月5日至2026年1月7日通过集中竞价方式减持公司股份755,700股，减持均价 为28.33元/股。本次权益变动后，该基金持有公司股份6,302,300股，占公司总股本比例由5.60%下降至 4.99%，持股比例已降至5%以下。本次权益变动不会导致公司实际控制人发生变化，且所持股份不存在 质押、冻结等权利限制情形。 ...

江苏爱朋医疗科技股份有限公司 简式权益变动报告书 上市公司名称：江苏爱朋医疗科技股份有限公司 股票上市地点：深圳证券交易所 股票简称：爱朋医疗 股票代码：300753 信息披露义务人：北京章泓私募基金管理有限公司-章泓精选 1 号私募证券投资基金 基金管理人：北京章泓私募基金管理有限公司 管理人注册地址：北京市房山区北京基金小镇大厦 C 座 441 股份变动性质：股份减少，持股比例降至 5%以下 签署日期：2026 年 1 月 8 日 1 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国公司法》《中华人民共和国证券法》（以 下简称"《证券法》"）、《上市公司收购管理办法》（以下简称"《收购管理办法》"）、 《公开发行证券的公司信息披露内容与格式准则第15号—权益变动报告书》（以下简称 "《第15号准则》"）及相关的法律法规编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违反信息 披露义务人章程或者内部规则中的任何条款，或与之相冲突。 三、依据《证券法》《收购管理办法》《第15号准则》的规定，本报告书已全面披 露了信息披露义务人在江苏爱朋医疗科技股份有限公司拥有权益的股 ...

证券代码：300753 证券简称：爱朋医疗 公告编号：2026-002 特别提示： 1、本次权益变动属于股东减持公司股份，不触及要约收购，不会导致公司控股股 东及实际控制人发生变化。 2、本次权益变动后，北京章泓私募基金管理有限公司-章泓精选 1 号私募证券投资 基金持有公司股份 6,302,300 股，占公司总股本的 4.9999%，不再是公司持股 5%以上的 股东。 江苏爱朋医疗科技股份有限公司（以下简称"公司"）于 2025 年 11 月 12 日在巨 潮资讯网（http://www.cninfo.com.cn）披露了《关于持股 5%以上股东减持股份的预披 露公告》（公告编号：2025-052），持有本公司 7,058,000 股（占公司总股本的 5.60%）的持股 5%以上股东北京章泓私募基金管理有限公司-章泓精选 1 号私募证券投 资基金（以下简称"章泓基金"），计划自上述公告披露之日起十五个交易日后的三 个月内以集中竞价交易方式减持所持有的本公司股份不超过 1,260,480 股（占公司总股 本的 1%）；以大宗交易方式减持所持有的本公司股份不超过 1,260,480 股（占公司总 股本的 1%） ...

Core Insights - The medical device sector experienced a rise of 1.14% on January 8, with Kangtong Medical leading the gains [1] - The Shanghai Composite Index closed at 4082.98, down 0.07%, while the Shenzhen Component Index closed at 13959.48, down 0.51% [1] Medical Device Sector Performance - Kangtong Medical (301515) closed at 25.48, up 20.02% with a trading volume of 123,300 shares and a transaction value of 291 million [1] - Yuanpeng Medical (300753) closed at 42.62, up 19.99% with a trading volume of 471,600 shares and a transaction value of 1.884 billion [1] - Kefu Medical (301087) closed at 54.00, up 13.52% with a trading volume of 174,300 shares and a transaction value of 92.86 million [1] - Shuoshi Biology (688399) closed at 77.21, up 13.31% with a trading volume of 73,500 shares and a transaction value of 550 million [1] - Anbiping (688393) closed at 27.60, up 6.73% with a trading volume of 69,500 shares and a transaction value of 189 million [1] Capital Flow Analysis - The medical device sector saw a net inflow of 533 million from institutional investors, while retail investors experienced a net outflow of 450 million [2][3] - Yuanpeng Medical had a net inflow of 225 million from institutional investors, but a net outflow of 103 million from retail investors [3] - Lepu Medical (300003) had a net inflow of 181 million from institutional investors, with a net outflow of 67.8 million from retail investors [3]

Group 1 - The brain-computer interface concept has seen a rise of 3.27%, ranking 9th among concept sectors, with 56 stocks increasing in value [1] - Notable stocks that reached the daily limit include Kangtong Medical, Aipeng Medical, and Puni Testing, all achieving a 20% increase, while Nanjing Panda, Pulit, and Innovation Medical also hit the limit [1] - Leading gainers in the sector include Kefu Medical, Yinkang Life, and Danghong Technology, with increases of 13.52%, 7.39%, and 6.67% respectively [1] Group 2 - The brain-computer interface sector attracted a net inflow of 1.115 billion yuan, with 41 stocks receiving net inflows, and 9 stocks exceeding 100 million yuan in net inflow [2] - The top stock for net inflow is Yanshan Technology, with a net inflow of 974 million yuan, followed by Seli Medical, Hainan Haiyao, and Aipeng Medical with net inflows of 314 million yuan, 272 million yuan, and 237 million yuan respectively [2] Group 3 - In terms of net inflow ratio, Innovation Medical, Seli Medical, and Beilu Pharmaceutical lead with ratios of 51.56%, 17.45%, and 16.93% respectively [3] - The brain-computer interface sector's top stocks by net inflow include Yanshan Technology with a 9.96% increase and a turnover rate of 34%, and Seli Medical with a 9.98% increase and a turnover rate of 33.31% [3][4]

Core Viewpoint - The artificial intelligence sector continues to show strong performance, with multiple stocks experiencing significant gains, reflecting positive market sentiment towards AI-related policies and developments [1][6]. Group 1: Stock Performance - On January 8, 21 stocks in the AI sector reached their daily limit up, including Aipeng Medical, Zhite New Materials, Meike Home, and others [1]. - Notably, Zhite New Materials, Meike Home, and others achieved a "4 consecutive limit up" status, while Far East Holdings reached a "3 consecutive limit up" [2]. - The top performers included Zhongcheng Technology (+22.67%), Aipeng Medical (+19.99%), and Zhite New Materials (+19.98%) [3]. Group 2: Policy Developments - On January 7, the Ministry of Industry and Information Technology and other departments released the "Implementation Opinions on the 'Artificial Intelligence + Manufacturing' Special Action," aiming to accelerate the integration of AI technology in manufacturing [1][4]. - The policy sets ambitious goals for 2027, including the development of 3 to 5 general large models for deep application in manufacturing and the creation of 100 high-quality industrial data sets [4][5]. - The initiative emphasizes the importance of innovation investment and the cultivation of globally influential enterprises in the AI sector [5]. Group 3: Market Dynamics - The listing of Zhipu AI on the Hong Kong Stock Exchange on January 8, with an opening price of HKD 120 per share and a market capitalization exceeding HKD 52.8 billion, is expected to inject new capital into the AI sector [6]. - The overall AI sector showed a strong upward trend on January 8, with significant capital flowing into application areas focused on industrial machinery, indicating a positive market response to policy directions [6]. - However, there is a noted structural differentiation within the sector, with some previously high-performing stocks experiencing profit-taking, suggesting potential short-term volatility risks [6][7]. Group 4: Industry Outlook - Dongxing Securities reports that the AI industry is currently in a phase of resonance among policy, technology, and demand, supported by top-down policy empowerment and potential funding [7]. - The industry is expected to maintain upward momentum, with a strong position in technology investment that is unlikely to be disrupted [7].

龙虎榜数据显示，该股因连续3个交易日内日收盘价格涨幅偏离值累计达30%、日换手率达30%上榜龙 虎榜2次，买卖居前营业部中，机构净买入4305.74万元，营业部席位合计净卖出1368.79万元。（数据 宝） | 日期 | 当日涨跌幅（%） | 换手率（%） | 主力资金净流入（万元） | | --- | --- | --- | --- | | 2026.01.07 | -11.11 | 44.91 | -7370.44 | | 2026.01.06 | 20.00 | 17.90 | 7057.72 | | 2026.01.05 | 20.00 | 21.38 | 15640.44 | | 2025.12.31 | -1.00 | 4.22 | -821.14 | | 2025.12.30 | -2.98 | 7.44 | -1537.45 | | 2025.12.29 | 1.80 | 10.77 | 1361.34 | | 2025.12.26 | -1.29 | 6.77 | -530.62 | | 2025.12.25 | 3.34 | 13.54 | -735.59 | | 2025.12.24 | ...

Group 1 - The core viewpoint of the article highlights a significant surge in A-share market stocks related to brain-computer interface (BCI) technology, driven by recent developments in the sector [1] - Aipeng Medical reached a 20% daily limit increase, while Kefu Medical rose over 15%, indicating strong investor interest in BCI-related companies [1] - Notable stocks such as Nanjing Panda, Pulite, and Innovation Medical achieved a 10% daily limit increase, reflecting a broader trend of positive market sentiment towards BCI stocks [1] Group 2 - The article mentions that on January 6, Strong Brain Technology, a leading company in the BCI field, announced the completion of approximately 2 billion RMB in financing, marking a significant milestone for the industry [1] - This financing round is noted to be the second largest globally in the BCI sector, only behind Neuralink, which is owned by Elon Musk [1] - The financing success of Strong Brain Technology is expected to further stimulate interest and investment in the BCI market, potentially leading to more advancements and innovations in the field [1]

脑机接口板块持续走强，爱朋医疗20cm涨停创新高，南京熊猫此前涨停录得4连板，创新医疗、岩山科 技、塞力医疗涨幅居前。 ...

Core Viewpoint - The ChiNext Index rose by 0.31% to close at 3329.69 points, with a total trading volume of 763.25 billion yuan, a decrease of 0.225 billion yuan from the previous trading day [1] Trading Performance - Among the 581 tradable stocks on the ChiNext, 581 stocks closed higher, with 24 stocks rising over 10%, including Gao Meng New Materials, Huarong Chemical, and Meihua Medical, which all hit the daily limit [1] - 794 stocks closed lower, with 4 stocks declining over 10%, including Rongke Technology, which hit the daily limit down [1] Turnover Rate - The average turnover rate for the ChiNext today was 5.16%, with 58 stocks having a turnover rate exceeding 20% [1] - The highest turnover rate was for C Xin Guangyi at 65.38%, with a closing price of 74.58 yuan and a trading volume of 1.509 billion yuan [1][4] - Other notable stocks with high turnover rates included Shaoyang Hydraulic (48.99%), Sanbo Brain Science (46.31%), and Aipeng Medical (44.91%) [1][4] Institutional Activity - Eight high-turnover stocks appeared on the Dragon and Tiger list, with institutional participation noted in several stocks [3] - Sanbo Brain Science had 4 institutional seats with a net buy of 266 million yuan, while Gao Meng New Materials also had 4 institutional seats with a net buy of 161 million yuan [3] Capital Flow - Among high-turnover stocks, 34 experienced net inflows from main funds, with significant inflows into Nanda Optoelectronics (871 million yuan), Dongfang Risheng (531 million yuan), and Xinwei Communication (394 million yuan) [4] - Conversely, Sanbo Brain Science, Blue Focus, and Huali Chuantong saw the largest net outflows, amounting to 685 million yuan, 631 million yuan, and 569 million yuan, respectively [4] Earnings Forecast - Three high-turnover stocks released earnings forecasts for 2025, all indicating profit growth [4] - Tian Su Measurement is expected to have the highest net profit growth rate at 10.31%, followed by C Xin Guangyi and Nabai Chuan with growth rates of 10.00% and 9.72%, respectively [4]